AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for EF-hand domain-containing protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5JVL4

UPID:

EFHC1_HUMAN

Alternative names:

Myoclonin-1

Alternative UPACC:

Q5JVL4; B4DMU3; F5GZD8; Q5XKM4; Q6E1U7; Q6E1U8; Q8WUL2; Q9NVW6

Background:

EF-hand domain-containing protein 1, also known as Myoclonin-1, plays a pivotal role in cell division and neuronal migration, essential for cortical development. It is involved in mitotic spindle organization and regulates cell morphology during brain development. Additionally, Myoclonin-1 contributes to calcium influx through CACNA1E, promoting programmed cell death, and is a crucial component of motile cilia, necessary for their function.

Therapeutic significance:

Myoclonin-1 is linked to juvenile myoclonic epilepsy 1 and juvenile absence epilepsy 1, conditions characterized by seizures with onset in adolescence. Understanding the role of Myoclonin-1 could open doors to potential therapeutic strategies for these epileptic disorders, highlighting its significance in neurology.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.